NEW YORK, Dec. 19, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its President and Chief Scientific Officer, Daniel L. Alkon, M.D., was honored by the International Association of Biomedical Sciences for his presentation at the University of Southern California-sponsored IABS Forum-2023, a gathering of world-renowned neuroscientists and academics discussing "New Concepts for the Treatment of Neurodegenerative Disorders."
Continue Reading
Preview
Source: PRNewswire
Giulio Maria Pasinetti, M.D., Ph.D. and Daniel Alkon, M.D. at IABS Forum-2023
The award was presented by Giulio Maria Pasinetti, M.D., Ph.D., Saunders Family Chair and Professor of Neurology at the Icahn School of Medicine at Mount Sinai, lead spokesperson for the event. Dr. Alkon was congratulated for his cutting-edge research in drug discovery and recognized for his decades of directing programs on the molecular and structural basis of associative memory at the National Neurologic Institute of the National Institutes of Health (NIH).
Dr. Alkon's presentation, titled "Chronic Alzheimer's Disease (AD) Patients Show Safe, Significant, and Persistent Benefit in 10-Month Bryostatin Trial," explored clinical data from the Company's NIH-sponsored, Phase 2 trial of its lead therapeutic candidate as a treatment for severe AD patients. In the trial, secondary efficacy endpoints were met with statistically significant benefits, p December 7-8, 2023 in Irvine, California, was co-sponsored by the University of Southern California (USC) School of Pharmacy and the International Association of Biomedical Sciences.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the anticipated Phase 1 trial of Bryostatin-1 in multiple sclerosis. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that the Company will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Additional factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand its business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement its business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.